K Moeremans

523 total citations
36 papers, 386 citations indexed

About

K Moeremans is a scholar working on Infectious Diseases, Oncology and Economics and Econometrics. According to data from OpenAlex, K Moeremans has authored 36 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Oncology and 8 papers in Economics and Econometrics. Recurrent topics in K Moeremans's work include Health Systems, Economic Evaluations, Quality of Life (7 papers), Neutropenia and Cancer Infections (4 papers) and Antifungal resistance and susceptibility (3 papers). K Moeremans is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (7 papers), Neutropenia and Cancer Infections (4 papers) and Antifungal resistance and susceptibility (3 papers). K Moeremans collaborates with scholars based in Belgium, United Kingdom and Netherlands. K Moeremans's co-authors include Lieven Annemans, Han Myint, Mark Lamotte, A Uyttebroeck, R. Pieters, Henk van den Berg, Henk van den Berg, Simon Van Belle, V. Cocquyt and Lazzaro Repetto and has published in prestigious journals such as Blood, Annals of Oncology and European Journal of Cancer.

In The Last Decade

K Moeremans

30 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K Moeremans Belgium 11 154 131 84 74 56 36 386
Amy Morris United States 12 57 0.4× 46 0.4× 71 0.8× 45 0.6× 59 1.1× 31 470
E De Cock United Kingdom 15 61 0.4× 34 0.3× 172 2.0× 36 0.5× 86 1.5× 50 571
Janna Manjelievskaia United States 12 67 0.4× 28 0.2× 103 1.2× 53 0.7× 27 0.5× 39 420
M. Papadimitriou Greece 15 115 0.7× 33 0.3× 43 0.5× 148 2.0× 30 0.5× 49 577
Stella Karuri United States 9 226 1.5× 77 0.6× 204 2.4× 56 0.8× 30 0.5× 14 578
Thierry Lobbedez France 10 58 0.4× 40 0.3× 60 0.7× 27 0.4× 39 0.7× 51 441
Liang Hua China 11 55 0.4× 95 0.7× 16 0.2× 55 0.7× 50 0.9× 24 345
Devin Incerti United States 13 45 0.3× 179 1.4× 31 0.4× 32 0.4× 77 1.4× 31 530
Caterina Mele Italy 7 38 0.2× 84 0.6× 77 0.9× 24 0.3× 28 0.5× 20 386
Luz-Ma-Adriana Balderas-Peña Mexico 13 39 0.3× 32 0.2× 140 1.7× 66 0.9× 48 0.9× 41 630

Countries citing papers authored by K Moeremans

Since Specialization
Citations

This map shows the geographic impact of K Moeremans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K Moeremans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K Moeremans more than expected).

Fields of papers citing papers by K Moeremans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K Moeremans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K Moeremans. The network helps show where K Moeremans may publish in the future.

Co-authorship network of co-authors of K Moeremans

This figure shows the co-authorship network connecting the top 25 collaborators of K Moeremans. A scholar is included among the top collaborators of K Moeremans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K Moeremans. K Moeremans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Moeremans, K, et al.. (2012). PSS8 Non-Interventional Study on the Burden of Illness in Diabetic Macular Edema (DME) in Belgium. Value in Health. 15(7). A569–A569.
4.
5.
6.
7.
Moeremans, K, et al.. (2007). ES8 COST-EFFECTIVENESS OF DARUNAVIR/R IN HIGHLY TREATMENT-EXPERIENCED HIV/AIDS PATIENTS IN DIFFERENT EUROPEAN HEALTH CARE SETTINGS. Value in Health. 10(6). A239–A239. 1 indexed citations
8.
Demarteau, Nadia, K Moeremans, & Lieven Annemans. (2007). Critical appraisal of scientific posters comparing anemia treatments for cancer patients: Applying ispor task force guidelines on methodological quality of retrospective studies. Critical Reviews in Oncology/Hematology. 63(2). 91–99. 1 indexed citations
9.
Repetto, Lazzaro, K Moeremans, & Lieven Annemans. (2006). European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment. Cancer Treatment Reviews. 32. S5–S9. 10 indexed citations
10.
Moeremans, K & Lieven Annemans. (2006). Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor?positive early breast cancer. Analysis based on the ATAC trial. International Journal of Gynecological Cancer. 16(s2). 576–578. 20 indexed citations
11.
Moeremans, K, et al.. (2006). Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfusion Medicine. 16(1). 17–30. 26 indexed citations
12.
Ethgen, Olivier, Erik Spaepen, K Moeremans, & Lieven Annemans. (2005). Economic impact of hospital malnutrition. Ghent University Academic Bibliography (Ghent University). 4 indexed citations
13.
Ethgen, Olivier, Erik Spaepen, K Moeremans, & Lieven Annemans. (2005). PMC13 ECONOMIC IMPACT OF HOSPITAL MALNUTRITION. Value in Health. 8(6). A68–A69. 2 indexed citations
14.
Moeremans, K, et al.. (2004). IN3 ECONOMIC EVALUATION OF INTRAVENOUS ITRACONAZOLE IN PRESUMED SYSTEMIC FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS IN GREECE. Value in Health. 7(6). 639–639. 1 indexed citations
15.
16.
Cocquyt, V., et al.. (2003). Postmenopausal breast cancer: incidence-based cost of illness. Journal of Medical Economics. 6(1-4). 15–30. 1 indexed citations
17.
Cocquyt, V., et al.. (2003). Long-term medical costs of postmenopausal breast cancer therapy. Annals of Oncology. 14(7). 1057–1063. 21 indexed citations
18.
Annemans, Lieven, K Moeremans, Mark Lamotte, et al.. (2003). Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Supportive Care in Cancer. 11(4). 249–257. 46 indexed citations
19.
Moeremans, K, Mark Lamotte, Henk van den Berg, et al.. (2002). Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin's Lymphoma in Four European Countries. Leukemia & lymphoma. 44(1). 77–83. 105 indexed citations
20.
Moeremans, K, et al.. (2000). Second Line Pharmacological Management of Paroxysmal and Persistent Atrial Fibrillation in France: A Cost Analysis. Value in Health. 3(6). 407–416. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amy Morris Breakdown of academic impact, for papers by E De Cock Breakdown of academic impact, for papers by Janna Manjelievskaia Breakdown of academic impact, for papers by M. Papadimitriou Breakdown of academic impact, for papers by Stella Karuri Breakdown of academic impact, for papers by Thierry Lobbedez Breakdown of academic impact, for papers by Liang Hua Breakdown of academic impact, for papers by Devin Incerti Breakdown of academic impact, for papers by Caterina Mele Breakdown of academic impact, for papers by Luz-Ma-Adriana Balderas-Peña
Rankless by CCL
2026